PUBLICATIONS

2015

  • Chen LQ, Randtke EA, Jones KM, Moon BF, Howison CM, Pagel MD.  Evaluations of tumor acidosis within in vivo tumor models using parametric maps generated with acidoCEST MRI.  Mol Imaging Biol 2015, Epub ahead of print.  PMID: 25622809, No PMCID.
  • Moon BF, Jones KM, Chen LQ, Liu P, Randtke EA, Howison CM, Pagel MD.  A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH.  Contrast Media Molec Imaging 2015, in press. No PMID.
  • Chen LQ, Pagel MD.  Evaluating pH in the Extracellular Tumor Microenvironment Using CEST MRI and Other Imaging Methods.  Adv Radiol, 2015, 206405,  DOI 10.1155/2015/206405, no PMID.

2014

  • Chen LQ, Howison CM, Jeffery JJ, Robey IF, Kuo PH, Pagel MD.  Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI.  Magn Reson Med 2014;72:1408-1417.  PMID: 24281951, PMCID 4033731, DOI: 10.1002/mrm.25053.
  • Randtke EA, Chen LQ, Correales LR, Pagel MD.  The Hanes-Woolf Linear QUESP method improves the measurements of fast chemical exchange rates with CEST MRI.  Magn Reson Med 2014;71(4):1603-1612.  PMID 23780911, PMCID 3784632, DOI: 10.1002/mrm.24792.
  • Randtke EA, Chen LQ, Pagel MD. The reciprocal linear QUEST analysis method facilitates the measurements of chemical exchange rates with CEST MRI.  Contrast Media Molec Imaging 2014;9:252–258.  PMID: 24700753, PMCID 3980514, DOI: 10.1002/cmmi.1566.
  • Jeffery JJ, Lux K, Vogel JS, Herrera WD, Greco S, Woo HH, Abu Shahin N, Pagel MD, Chambers SK.  Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging.  Exp Bio Med 2014;239:404–413.  PMID: 24599884, No PMCID, DOI: 10.1177/1535370214522588.
  • Lee J, Cárdenas-Rodríguez J, Pagel MD, Platt S, Marc Kent M, Zhao Q.  Comparison of analytical and numerical analysis of the reference region model for DCE-MRI.  Magn Reson Imaging 2014;32(7):845-853. PMID: 24925838, No PMCID, DOI: 10.1016/j.mri.2014.04.007.
  • Zhang X, Pagel MD, Baker AM, Gillies RJ.  Reproducibility of magnetic resonance perfusion imaging. PLOS One 2014;9(2):e89797.  PMID: 24587040, PMCID 3934952, DOI: 10.1371/journal.pone.0089797.
  • Hingorani DV, Yoo B, Bernstein AS, Pagel MD.  Detecting enzyme activities with exogenous MRI contrast agents.  Chem Euro J 2014;20:9840-9850.  PMID: 24990812, PMCID 24990812, DOI: 10.1002/chem.201402474.
  • Chen LQ, Howison CM, Spier C, Stopeck AT, Malm SW, Pagel MD, Baker AF.  Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.  Leukemia Lymphoma 2014, Epub ahead of print.  PMID: 25130478, No PMCID.
  • Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle R, Guzman R, Pagel MD, Meuillet EJ.  Nanoparticle Delivery of a AKT/PDK1 Inhibitor Improves the Therapeutic Effect Against Pancreatic Cancer.  Int J Nanotech 2014;9:5653–5665. PMID: 25516710, PMCID 4263440
  • Jones KM, Randtke EA, Howison CM, Cárdenas-Rodríguez J, Sime PJ, Kottmann RM, Pagel MD.  Measuring Extracellular pH in a Lung Fibrosis Model with acidoCEST MRI.  Molec Imaging Biol 2015;17:177-184. PMID: 25187227, No PMCID.
  • Hingorani DV, Bernstein AS, Pagel MD.  A review of responsive MRI contrast agents: 2005-2014.  Contrast Media Molec Imaging 2014, Epub ahead of print.   PMID: 25355685, PMCID 4414668.

2013

  • Cárdenas-Rodríguez J, Howison CM, Matsunaga TO, Pagel MD.  A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents.  Magn Reson Imaging 2013;31:900-910.  PMID 23583323, PMCID 3721191, DOI: 10.1016/j.mri.2012.12.002.
  • Cárdenas-Rodríguez J, Howison CM, Pagel, MD. A linear algorithm of the reference region model for DCE-MRI is robust and relaxes requirements for temporal resolution. Magn Reson Imaging 2013;31(4):497-507.  PMID 23228309, PMCID 3639320, DOI: 10.1016/j.mri.2012.10.008.
  • Yoo B, Pagel MD.  Lanthanide-mediated dephosphorylation used for peptide cleavage during solid phase peptide synthesis.  Molecules 2013;18:3894-3905.  PMID 23549296, PMCID 3955260, DOI: 10.3390/molecules18043894.
  • Hingorani DV, Randtke EA, Pagel MD.  A catalyCEST MRI contrast agent that detects the enzyme- catalyzed creation of a covalent bond.  J Am Chem Soc 2013;135(17):6396–6398.  PMID 23601132, PMCID 23601132 DOI: 10.1021/ja400254e.
  • Yoo B, Sheth VR, Howison CM, Douglas MJK, Pineda CT, Maine EA, Baker AF, Pagel MD.  Detection of in vivo enzyme activity with catalyCEST MRI.  Mag Reson Med 2013;71(3):1221-1230.  PMID 23640714, PMCID 3742626 DOI: 10.1002/mrm.24763.
  • Hingorani DV, Gonzalez SI, Li JF, Pagel MD.  Sensing lanthanide metal content in biological tissues with magnetic resonance spectroscopy.  Sensors 2013;13:13732-13743.  PMID 24152931, PMCID 3859089, DOI: 10.3390/s131013732.
  • Leung HM, Schafer R, Pagel MD, Robey IF, Gmitro AF.  Multimodality pH imaging in a mouse dorsal skin fold window chamber model. Proc SPIE 8574, Multimodal Biomedical Imaging VIII, 85740L.

2012

  • Sheth VR, Pagel MD.  CEST & PARACEST MRI contrast agents for imaging cancer biomarkers. In: Molecular Imaging Probes for Cancer Research (Chen X, ed.), World Scientific Publishing, 2012.
  • Sheth VR, Li Y, Chen LQ, Howison CM, Flask CA, Pagel MD. Measuring in vivo tumor pHe with CEST-FISP MRI. Magn Reson Med 2012;67:760–768.  PMID 22028287, PMCID 3572795.
  • Liu G, Li Y, Sheth VR, Pagel MD. Imaging in vivo extracellular pH with a Single PARACEST MRI Contrast Agent.  Molec Imaging 2012;11(1):47-57.  PMID 21651182, No PMCID .
  • Sheth VR, Liu G, Li Y, Pagel MD. Improved pH measurements with a single PARACEST MRI contrast agent.  Contrast Media Molec Imaging 2012;7:26–34.  PMID 22344877, No PMCID.
  • Cárdenas-Rodríguez J, Li Y, Galons JP, Connell H, Pagel MD, Baker AF. Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.  Magn Reson Imaging 2012;30:1002-1009.  PMID 22554971, PMCID 3402593.
  • Ali MM, Bhuiyan MPI, Janic B, Varma NRS, Mikkelsen T, Ewing JR, Knight RA, Pagel MD, Arbab AS.  A nano-sized PARACEST-fluorescence imaging contrast agent facilitates & validates in vivo CEST MRI detection of glioma.  Nanomed 2012;7(12):1827-37.  PMID 22891866, PMCID 3526688.
  • Stephen R, Pagel MD, Brown K, Baker AF, Meuillet EJ, Gillies RJ. Monitoring the development of xenograft triple negative breast cancer models using diffusion-weighted MRI.  Exp Biol Med 2012;237(11):1273-80.  PMID 23239438, PMCID 4091981.
  • Cárdenas-Rodríguez J, Howison CM, Pagel, MD. A linear algorithm of the reference region model for DCE-MRI is robust and relaxes requirements for temporal resolution. Magn Reson Imaging 2013;31(4):497-507.  PMID 23228309, PMCID 3639320, DOI: 10.1016/j.mri.2012.10.008.
  • Cárdenas-Rodríguez J, Howison CM, Matsunaga TO, Pagel MD.  A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents.  Magn Reson Imaging 2013;31:900-910.  PMID 23583323, PMCID 3721191, DOI: 10.1016/j.mri.2012.12.002.

2011

  • Li Y, Sheth VR, Liu G, Pagel MD. A self-calibrating PARACEST MRI contrast agent that detects esterase enzyme activity.  Contrast Media Molec Imaging 2011;6(4):219-228.  PMID 21861282, No PMCID.
  • Pagel MD.  The hope and hype of multimodality imaging contrast agents. Nanomed 2011;6(6):945–948.  PMID 21955073, No PMCID.
  • Pagel MD. Responsive paramagnetic chemical exchange saturation transfer MRI contrast agents. Imaging Med 2011;3(4):377–380.  No PMID, No PMCID.
  • Josan JS, De Silva CR, Yoo B, Lynch RM, Pagel MD, Vagner J, Hruby VJ.  Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.  Methods Molecular Biol 2011;716:89-126.  PMID 21318902, PMCID 3365840.
  • Pagel MD, Basilion JP.  Non-invasive imaging of genes and gene expression with magnetic resonance imaging and magnetic resonance spectroscopy.  In: Molecular Imaging with Reporter Genes (Gambhir SS, Yaghoubi SS, Eds.), Cambridge University Press, 2011.
  • Shah T, Lu L, Dell K, Pagel MD, Griswold M, Flask CA.  CEST-FISP: A novel technique for rapid chemical exchange saturation transfer (CEST) MRI at 7T.  Magn Reson Med 2011;65:432–437.  PMID 20939092, PMCID 3760737.

2009

  • Liu G, Ali, M, Yoo B, Griswold MA, Tkach JA, Pagel MD. PARACEST MRI with improved            temporal resolution.  Magn Reson Med 2009;61:399-408.  PMID 19165903, No PMCID
  • Ali MM, Yoo B, Pagel MD. Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.  Molec Pharmaceutics 2009;6(5):1409-1416.  PMID 19298054, PMCID 4216567.
  • Yoo B, Sheth V, Pagel MD. An amine-derivatized, DOTA-loaded polymeric support for Fmoc solid phase peptide synthesis. Tet Lett 2009;50:4459–4462.  PMID 20161272, PMCID 2702766.
  • Ali MM, Liu G, Shah T, Flask CA, Pagel MD. Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies. Acc Chem Res 2009;42(7):915-924.  PMID 19513717, No PMCID.

2008

  • Yoo B, Pagel MD.  An overview of responsive MRI contrast agents for molecular imaging.  Front Biosci 2008;13:1733-1752.  PMID 17981664, No PMCID.
  • Sheth VR, van Heeckeren RC, Wilson AG, van Heeckeren AM, Pagel MD, Monitoring infection and inflammation in murine models of cystic fibrosis with magnetic resonance imaging, J Magn Reson Imaging 2008;28(2):527-532.  PMID 18666218, PMCID 2538376.

2007

  • Yoo B, Pagel MD.  Peptidyl molecular imaging contrast agents using a new solid phase peptide synthesis approach.   Bioconj Chem 2007;18:903-911.  PMID 17330953, PMCID 2584118.
  • Yoo B, Raam M, Rosenblum R, Pagel MD. Enzyme-responsive PARACEST MRI contrast agents: A new biomedical imaging approach for studies of the proteasome.  Contrast Media Molec Imaging 2007;2:189-198.  PMID 17712869, No PMCID.
  • Liu G, Li Y, Pagel MD. Design and characterization of new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide. Magn Reson Med 2007;58:1249-1256.  PMID 18046705, No PMCID.

2006

  • Pagel MD, Baldwin SJ, Rader RK, Kotyk JJ. Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis. NMR Biomed 2006;19:1-9.  PMID 16411252, No PMCID.
  • Yoo B, Pagel MD. A facile synthesis of α-amino-DOTA as a versatile molecular imaging probe. Tet Lett 2006;47:7327-7330.  No PMID.
  • Yoo B, Pagel MD. A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc 2006;128(43):14032-14033.  PMID 17061878, No PMCID.

2005

  • Ai H, Flask C, Weinberg B, Shuai X, Pagel, MD, Farrell D, Duerk J, Gao J.  Magnetite-loaded polymeric micelles as ultrasensitive magnetic-resonance probes.  Advanced Mat 2005;17(16):1949-1952.  No PMID.
  • Kotyk JJ, Pagel MD, Deppermann KL, Colletti RF, Hoffman NG, Yannakakis EJ, Das PK, Ackerman JJH. High-throughput determination of oil content in corn kernels using nuclear magnetic resonance imaging. J Am Oil Chem Soc 2005;82:855-862.  No PMID

2004

  • Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR, Goldberg SF, Gilman VR, Sosnowski DM, Campo DA, Gay CV, Budgeon LR, Mercer R, Jewell J, Mastro AM, Donahue HJ, Erin N, Debies MT, Meehan WJ, Jones AL, Mbalaviele G, Nickols A, Christensen ND, Melly R, Beck LN, Kent J, Rader RK, Kotyk JJ, Pagel MD, Westlin WF, Griggs DW. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Met 2004;21:119-28.  PMID 15168729, No PMCID.
  • Davis TW, O’Neal JM, Pagel MD, Zweifel, BS, Mehta PP, Heuvelman DM, Masferrer JL. Synergy between celecoxib and radiotherapy results from inhibition of COX-2 derived PGE2, a survival factor for tumor and associated vasculature.  Cancer Res 2004;64:279-285.  PMID 14729635, No PMCID